Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lakshminarayan

Showing results (511-520 of 585) with videos related to

Pageof 59
Sort By:
Journal of Inherited Metabolic Disease|April 11, 2015
Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuriaJean-Baptiste Arnoux, Kim-Hanh Le Quan Sang, Anais Brassier, et al.
Human Molecular Genetics|May 25, 2026
Specific knockout of kidney homogentisate 1,2-dioxygenase reveals that local metabolism of tyrosine and homogentisic acid is negligible in alkaptonuriaDominic A Rutland, Brendan P Norman, Juliette H Hughes, et al.
Metabolites|August 25, 2022
Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone TreatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Mayo Clinic Proceedings|May 17, 2025
Polypharmacy and Potentially Inappropriate Medications in Adults ≥75 Years of Age by Dementia and Frailty Status: The ARIC StudyPamela L Lutsey, Jeffrey R Misialek, Eric A Whitsel, et al.
Medrxiv : the Preprint Server for Health Sciences|May 9, 2025
Assessment of the Modified Rankin Scale in Electronic Health Records with a Fine-tuned Large Language ModelLuis Silva, Marcus Milani, Sohum Bindra, et al.
Metabolites|October 27, 2022
Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of AlkaptonuriaLakshminarayan R Ranganath, Andrew T Hughes, Andrew S Davison, et al.
Tobacco Prevention & Cessation|November 16, 2022
Prevalence and factors associated with tobacco use among beneficiaries attending the youth mental health promotion clinics (Yuvaspandana Kendra) in India: A case-record analysisGautham M Sukumar, Pradeep Banandur, Vaishali Dagar, et al.
Clinical Chemistry|February 21, 2019
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to AlkaptonuriaBrendan P Norman, Andrew S Davison, Gordon A Ross, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|December 16, 2017
Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney DiseaseChristine M Burns, David S Knopman, David E Tupper, et al.
Journal of Inherited Metabolic Disease|September 11, 2019
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuriaJuliette H Hughes, Peter J M Wilson, Hazel Sutherland, et al.
Pageof 59

Showing results (511-520 of 585) with videos related to

Sort By:
Pageof 59
Journal of Inherited Metabolic Disease|April 11, 2015
Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuriaJean-Baptiste Arnoux, Kim-Hanh Le Quan Sang, Anais Brassier, et al.
Human Molecular Genetics|May 25, 2026
Specific knockout of kidney homogentisate 1,2-dioxygenase reveals that local metabolism of tyrosine and homogentisic acid is negligible in alkaptonuriaDominic A Rutland, Brendan P Norman, Juliette H Hughes, et al.
Metabolites|August 25, 2022
Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone TreatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Mayo Clinic Proceedings|May 17, 2025
Polypharmacy and Potentially Inappropriate Medications in Adults ≥75 Years of Age by Dementia and Frailty Status: The ARIC StudyPamela L Lutsey, Jeffrey R Misialek, Eric A Whitsel, et al.
Medrxiv : the Preprint Server for Health Sciences|May 9, 2025
Assessment of the Modified Rankin Scale in Electronic Health Records with a Fine-tuned Large Language ModelLuis Silva, Marcus Milani, Sohum Bindra, et al.
Metabolites|October 27, 2022
Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of AlkaptonuriaLakshminarayan R Ranganath, Andrew T Hughes, Andrew S Davison, et al.
Tobacco Prevention & Cessation|November 16, 2022
Prevalence and factors associated with tobacco use among beneficiaries attending the youth mental health promotion clinics (Yuvaspandana Kendra) in India: A case-record analysisGautham M Sukumar, Pradeep Banandur, Vaishali Dagar, et al.
Clinical Chemistry|February 21, 2019
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to AlkaptonuriaBrendan P Norman, Andrew S Davison, Gordon A Ross, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|December 16, 2017
Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney DiseaseChristine M Burns, David S Knopman, David E Tupper, et al.
Journal of Inherited Metabolic Disease|September 11, 2019
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuriaJuliette H Hughes, Peter J M Wilson, Hazel Sutherland, et al.
Pageof 59